Granisetron Viatris

Granisetron Viatris is an oral prescription medication whose active ingredient is granisetron, a selective 5‑HT3 receptor antagonist. Marketed in the European Union, it is used to prevent nausea and vomiting linked to chemotherapy and postoperative recovery. The product belongs to the antiemetic class and works by blocking serotonin receptors in the nervous system. It is supplied without a fixed dosage strength, allowing clinicians to tailor dosing.

Granisetron Viatris is indicated for the prevention of nausea and vomiting in specific clinical situations.

- Prevention of chemotherapy‑induced nausea and vomiting (CINV) in adult patients. - Prevention of postoperative nausea and vomiting (PONV) following surgical procedures. - Use as part of a multimodal antiemetic regimen when moderate to high emetogenic risk is anticipated. - Adjunct therapy for patients receiving radiation therapy who experience nausea. - Optional use in diagnostic procedures that may trigger serotonin‑mediated emesis. - Management of nausea associated with diagnostic imaging agents that stimulate serotonin release.

The safety profile of Granisetron Viatris includes both frequently observed and less common adverse events, most of which are mild and transient.

Common: - Headache, often mild and transient. - Constipation or mild abdominal discomfort, usually resolving without intervention. - Dizziness or light‑headed feeling, particularly when standing quickly. - Fatigue or general tiredness. - Dry mouth. - Transient visual disturbances such as blurred vision.

Serious: - Allergic reactions such as rash, itching, or swelling, which may require medical attention. - Cardiac arrhythmias, including QT interval prolongation, especially in patients with pre‑existing heart conditions. - Severe constipation leading to bowel obstruction, necessitating prompt evaluation. - Serotonin syndrome when combined with other serotonergic agents, presenting with agitation, hyperreflexia, and fever. - Severe hypotension, potentially causing dizziness or fainting. - Hepatic enzyme elevations, usually detected on laboratory testing.

When prescribing Granisetron Viatris, clinicians should consider several precautionary measures to ensure safe use.

- Assess patient history for hypersensitivity to granisetron or other 5‑HT3 antagonists. - Evaluate cardiac risk, especially QT prolongation, before initiating therapy. - Use caution in patients with hepatic impairment; dose adjustments may be required. - Monitor for signs of severe constipation or bowel obstruction during treatment. - Consider potential serotonin syndrome when used with other serotonergic drugs. - Use the lowest effective dose for the shortest duration needed. - Advise patients to report any rash, swelling, or difficulty breathing promptly.

Granisetron Viatris may interact with other medications; awareness of these interactions helps prevent adverse effects.

Avoid: - Other 5‑HT3 antagonists, as combined use offers no added benefit and may increase toxicity. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) that can reduce granisetron plasma levels.

Use with caution: - Antidepressants that increase serotonin (SSRIs, SNRIs, MAO inhibitors) due to risk of serotonin syndrome. - Antiarrhythmic agents that affect QT interval (e.g., amiodarone, quinidine). - Opioids, which can potentiate nausea and may require dose adjustments. - Anesthetics used during surgery, as they may enhance emetogenic stimuli. - Anticholinergic agents, which may exacerbate constipation.